Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

DOI: 10.1046/j.1365-2141.2001.02850.x
British Journal of Haematology, 2001, 113, 983-8.

#	Paper	IF	Citations
316	Genomic structure of human FLT3: implications for mutational analysis. *British Journal of Haematology*, **2001**, 113, 1076-7	4.5	60
315	New therapies in leukemia: renewed hope. **2002**, 11, 583-7		
314	The roles of FLT3 in hematopoiesis and leukemia. **2002**, 100, 1532-42		1128
313	Role of FLT3 in leukemia. **2002**, 9, 274-81		156
312	Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. **2002**, 100, 2393-8		255
311	Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. **2002**, 100, 2387-92		242
310	A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. **2002**, 100, 3423-5		90
309	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. **2002**, 100, 4372-80		690
308	Genetics of myeloid leukemias. **2002**, 3, 179-98		386
307	CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). **2002**, 1, 421-32		278
306	Genetic profile of acute myeloid leukemia. **2002**, 6, 3-25; discussion 86-7		9
305	Class III receptor tyrosine kinases: role in leukaemogenesis. *British Journal of Haematology*, **2002**, 116, 744-57	4.5	86
304	Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. **2002**, 16, 1699-704		101
303	Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. **2002**, 16, 2027-36		92
302	Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. **2002**, 21, 3314-33		148
301	An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. **2002**, 21, 5981-9		54
300	Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. **2002**, 100, 59-66		798

299	Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications. **2003**, 20, 311-24		5
298	The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. **2003**, 71, 163-73		14
297	Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. **2003**, 98, 1206-16		75
296	Molecular targets in acute myelogenous leukemia. **2003**, 17, 15-23		29
295	Receptor tyrosine kinases in normal and malignant haematopoiesis. **2003**, 17, 241-8		53
294	Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. *British Journal of Haematology*, **2003**, 120, 464-70	4.5	27
293	Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. *British Journal of Haematology*, **2003**, 121, 775-7	4.5	253
292	Flt3 mutations and leukaemia. *British Journal of Haematology*, **2003**, 122, 523-38	4.5	106
291	FLT3 mutations in acute myeloid leukemia cell lines. **2003**, 17, 120-4		203
290	FLT3-TKD mutation in childhood acute myeloid leukemia. **2003**, 17, 883-6		62
289	Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. **2003**, 17, 1482-98		36
288	FLT3: ITDoes matter in leukemia. **2003**, 17, 1738-52		392
287	Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. **2003**, 17, 2492-9		53
286	The role of FLT3 in haematopoietic malignancies. **2003**, 3, 650-65		657
285	Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. **2003**, 5, 96-102		147
284	FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. **2003**, 16, 409-17		23
283	Immunophenotyping as a guide for targeted therapy. **2003**, 16, 629-44		4
282	FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. **2003**, 102, 2198-204		85

281	Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. **2003**, 101, 3164-73		250
280	Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. **2003**, 44, 905-13		40
279	Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations. **2003**, 34, 352-8		9
278	Novel FLT3 tyrosine kinase inhibitors. **2003**, 12, 1951-62		26
277	Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. **2003**, 10, 31-9		14
276	Mutational profiling in the human genome. **2003**, 68, 23-9		6
275	The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. **2003**, 101, 1494-504		99
274	Kinase inhibitors in leukemia. **2004**, 51, 1-33		
273	Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias. **2004**, 8, 221-39		15
272	Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. **2004**, 10, 1326-32		48
271	Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. *British Journal of Haematology*, **2004**, 124, 481-4	4.5	47
270	FLT3 mutations in myeloid sarcoma. *British Journal of Haematology*, **2004**, 126, 785-91	4.5	43
269	Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. **2004**, 18, 466-75		126
268	FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. **2004**, 23, 3338-49		94
267	Concepts of human leukemic development. **2004**, 23, 7164-77		178
266	Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. **2004**, 72, 307-13		46
265	Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. **2004**, 23, 153-65		8
264	Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. **2004**, 23, 139-52		45

263	Tyrosine kinases in AML: where do they fit in?. **2004**, 28, 217-8	2
262	Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. **2004**, 28, 1069-74	30
261	FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. **2004**, 40, 707-21, discussion 722-4	54
260	The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. **2004**, 13, 169-78	360
259	Emerging treatments in acute myeloid leukaemia. **2004**, 9, 55-71	14
258	Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. **2004**, 103, 2266-75	62
257	FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. **2004**, 103, 267-74	166
256	Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. **2004**, 103, 1883-90	132
255	Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. **2004**, 104, 1137-44	45
254	Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. **2004**, 103, 3669-76	542
253	Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. **2004**, 104, 2867-72	74
252	Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. **2004**, 104, 2646-54	95
251	In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. **2004**, 104, 1145-50	192
250	Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. **2004**, 104, 1855-8	72
249	Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. **2005**, 12, 7-13	31
248	After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. **2005**, 105, 22-30	50
247	FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). **2005**, 105, 3679-85	87
246	FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. **2005**, 105, 812-20	164

245	AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. **2005**, 106, 265-73		197
244	Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. **2005**, 105, 77-84		46
243	RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. **2005**, 105, 2107-14		61
242	FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. **2005**, 105, 4792-9		162
241	Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. **2005**, 29, 1393-8		30
240	Clinical significance of FLT3 in leukemia. **2005**, 82, 85-92		53
239	Signal transduction of oncogenic Flt3. **2005**, 82, 93-9		69
238	Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?. *British Journal of Haematology*, **2005**, 128, 18-34	4.5	62
237	Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. *British Journal of Haematology*, **2005**, 128, 318-23	4.5	24
236	Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. *British Journal of Haematology*, **2005**, 129, 60-5	4.5	71
235	A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia. **2005**, 19, 480-1		13
234	Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. **2005**, 19, 930-5		21
233	Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant. **2005**, 24, 8144-53		12
232	Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. **2005**, 162, 127-34		20
231	Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. **2005**, 145, 295-304		20
230	CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. **2005**, 64, 18-27		22
229	The molecular pathogenesis of acute myeloid leukemia. **2005**, 56, 195-221		54
228	Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. **2005**, 131, 279-83		7

227	Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. **2005**, 44, 142-6		16
226	The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. **2005**, 65, 7338-47		37
225	FLT3/ITD mutation signaling includes suppression of SHP-1. **2005**, 280, 5361-9		33
224	CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. **2005**, 11, 5281-91		93
223	Recent advances in targeted therapy of human myelogenous leukaemia. **2005**, 9, 1147-63		2
222	Mutant FLT3 signaling contributes to a block in myeloid differentiation. **2005**, 46, 1679-87		27
221	Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. **2005**, 65, 1514-22		44
220	Genetics of myeloid malignancies: pathogenetic and clinical implications. **2005**, 23, 6285-95		281
219	[FLT3 Gene Mutations as a Prognostic Factor for Acute Myeloid Leukemia.]. **2006**, 26, 233-40		2
218	Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. **2006**, 111, 233-49		7
217	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. **2006**, 107, 293-300		217
216	Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. **2006**, 107, 3700-7		96
215	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. **2006**, 108, 3674-81		224
214	Clinical implications of FLT3 mutations in pediatric AML. **2006**, 108, 3654-61		302
213	The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. **2006**, 108, 3494-503		101
212	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. **2006**, 108, 3262-70		339
211	Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. *British Journal of Haematology*, **2006**, 134, 302-6	4.5	31
210	ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells. **2006**, 30, 633-42		8

209	Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations. **2006**, 30, 1541-6	7
208	Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3. **2006**, 84, 54-9	5
207	Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. **2006**, 83, 301-8	46
206	Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. **2006**, 34, 1360-76	27
205	Point mutations of protein kinases and individualised cancer therapy. **2006**, 7, 2243-61	23
204	IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. **2006**, 66, 4843-51	37
203	Emerging Flt3 kinase inhibitors in the treatment of leukaemia. **2006**, 11, 153-65	20
202	Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. **2006**, 203, 371-81	164
201	Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. **2006**, 12, 7018-24	20
200	Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. **2007**, 67, 9852-61	27
199	FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. **2007**, 110, 1262-70	239
198	Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. **2007**, 109, 1643-52	132
197	Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. **2007**, 110, 686-94	26
196	Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. **2007**, 110, 4476-9	37
195	Insight into the molecular pathogenesis of myeloid malignancies. **2007**, 14, 90-7	20
194	Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. **2007**, 251, 323-9	102
193	Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations. **2007**, 48, 2418-23	3
192	Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. **2007**, 25, 30-7	32

191	4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors. **2007**, 17, 4861-5	16
190	Pediatric oncology. **2007**, 11, 424-32	13
189	HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. **2007**, 31, 921-9	13
188	Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). **2007**, 31, 791-7	7
187	Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD. **2007**, 21, 2246-57	21
186	Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. **2007**, 86, 311-27	39
185	Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. **2007**, 86, 741-7	23
184	[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets]. **2008**, 37, 394-403	
183	Systemic cancer therapy: evolution over the last 60 years. **2008**, 113, 1857-87	42
182	FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns. **2008**, 47, 64-70	25
181	Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. **2008**, 99, 479-85	31
180	Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. **2008**, 80, 208-15	61
179	Akt as a therapeutic target in cancer. **2008**, 12, 1139-65	114
178	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. **2008**, 13, 1-12	1
177	Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. **2008**, 14, 4437-45	21
176	FLT3 inhibitors in acute myeloid leukemia. **2008**, 1, 153-60	8
175	Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. **2008**, 28, 5494-506	72
174	Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. **2008**, 49, 2291-7	21

173	Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. **2008**, 49, 852-63	41
172	Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. **2008**, 111, 2527-37	290
171	Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. **2008**, 112, 814-21	88
170	Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia. **2008**, 23, 833-7	11
169	Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis. **2008**, 9, 2194-204	12
168	Occurrence of Acute Myeloid Leukemia in Young Pregnant Women. **2008**, 1, CMBD.S823	
167	Sequence and structure signatures of cancer mutation hotspots in protein kinases. **2009**, 4, e7485	57
166	Prognostic Significance of FLT3 Internal Tandem Duplication in Acute Myeloid Leukemia with Normal Karyotype. **2009**, 44, 74	
165	Investigational drugs targeting FLT3 for leukemia. **2009**, 18, 1445-56	11
164	Conventional and Real-Time Polymerase Chain Reaction. **2009**, 33-49	4
163	RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. **2009**, 37, 65-77	39
162	Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. **2009**, 26, 460-2	17
161	Mechanisms of resistance to FLT3 inhibitors. **2009**, 12, 8-16	45
160	Cancer driver mutations in protein kinase genes. **2009**, 281, 117-27	65
159	Lestaurtinib: a multi-targeted FLT3 inhibitor. **2009**, 2, 17-26	12
158	Structural and functional alterations of FLT3 in acute myeloid leukemia. **2009**, 15, 4263-9	169
157	Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. **2009**, 113, 4074-7	91
156	Fathoming flt3. **2009**, 113, 3889-90	1

155	Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. **2009**, 114, 2386-92		203
154	FLT3 as a therapeutic target in AML: still challenging after all these years. **2010**, 116, 5089-102		280
153	Molecular genetics. 90-110		1
152	The role of molecular tests in acute myelogenous leukemia treatment decisions. **2010**, 5, 109-17		24
151	Targeted signal transduction therapies in myeloid malignancies. **2010**, 12, 358-65		8
150	Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. **2010**, 14, 504-27		45
149	Effects of indirubin derivatives on the FLT3 activity and growth of acute myeloid leukemia cell lines. **2010**, 71, 221-227		7
148	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. **2010**, 34, 752-6		85
147	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. **2010**, 28, 1856-62		298
146	Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases. *Cancers*, **2011**, 3, 1195-231	6.6	16
145	The Molecular Biology of Acute Myeloid Leukemia. **2011**, 86-102		
144	Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features. **2011**, 28, 544-51		13
143	FLT3 mutations in canine acute lymphocytic leukemia. **2011**, 11, 38		20
142	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. **2011**, 117, 2145-55		81
141	Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). **2011**, 19, 4173-82		15
140	Acute Myeloid Leukemia Associated With Near-Tetraploid Karyotype and Mutations in the FLT3 Gene. **2011**, 42, 540-543		1
139	Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. **2011**, 16, 407-23		6
138	FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. **2011**, 16, 1162-74		41

137	A FLT3-inhibitory constituent from the rhizomes of Anemarrhena asphodeloides. **2011**, 26, 445-8		4
136	Analysis of Chromosomal Aberrations and FLT3 gene Mutations in Childhood Acute Myelogenous Leukemia Patients. **2012**, 29, 225-35		3
135	The Frequency of Mutations in Exon 11 of the c-kit Gene in Patients With Leukemia. **2012**, 29, 10-6		
134	STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells. **2012**, 1, 13-22		18
133	Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. **2012**, 25, 1405-12		36
132	Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. **2012**, 120, 3069-79		45
131	3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). **2012**, 22, 4654-9		6
130	A study of KIT activating mutations in acute myeloid leukemia M0 subtype in north India. **2012**, 13, 133-138		
129	Development of Amplifi cation-Based Molecular Genetic Testing in Hematology. **2012**, 155-167		
128	Molecular Diagnostics of Acute Myeloblastic Leukemia. **2012**, 387-410		
127	Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. **2012**, 26, 2176-85		98
126	An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. **2012**, 6, e8		104
125	Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. **2012**, 685-9		0
124	Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples. **2012**, 5, 6		5
123	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. **2012**, 26, 1247-54		109
122	Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. **2012**, 36, 316-23		47
121	Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. *British Journal of Haematology*, **2012**, 158, 555-8	4.5	5
120	Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia. **2013**, 54, 145-52		31

119	Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. **2013**, 27, 48-55	68
118	Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). **2013**, 21, 2856-67	13
117	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?. **2013**, 2013, 220-6	164
116	Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. **2013**, 35, 581-8	25
115	Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). **2013**, 25, 195-204	18
114	FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. **2013**, 27, 260-8	88
113	Emergence of crenolanib for FLT3-mutant AML. **2013**, 122, 3547-8	16
112	FMS-related tyrosine kinase 3. 144-161	
111	The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. **2013**, 313-8	17
110	FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance. **2014**, 6, e2014038	7
109	Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. **2014**, 7, 439-64	16
108	The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. **2014**, 5, 65-77	128
107	Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients. **2014**, 2014, 141360	13
106	The Biology and Targeting of FLT3 in Pediatric Leukemia. **2014**, 4, 263	43
105	FLT3 inhibitors in AML: are we there yet?. **2014**, 9, 174-85	27
104	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. **2014** , 55, 243-55	70
103	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. **2014**, 123, 94-100	175
102	Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations. **2015**, 100, 151-61	10

101	Next-generation sequencing-based panel testing for myeloid neoplasms. **2015**, 10, 104-11	25
100	Correlation between the Stereochemistry and Bioactivity in Octahedral Rhodium Prolinato Complexes. **2015**, 54, 8111-20	12
99	Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia. **2015**, 144, 539-54	8
98	Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. **2015**, 29, 1-9	41
97	FLT3 Inhibitors for Treating Acute Myeloid Leukemia. **2016**, 16, 543-549	30
96	Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. **2016**, 9, 61	43
95	FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. **2016**, 76, 6471-6482	61
94	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. **2016**, 6, 1334-1341	94
93	Resistance to FLT3 Inhibitors. **2016**, 131-145	
92	The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. **2016**, 32, 38-40	0
91	Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. **2017**, 7, 868-883	69
90	The Future of Targeting FLT3 Activation in AML. **2017**, 12, 153-167	32
89	Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. **2017**, 2, 1985-2009	8
88	Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. **2017**, 35, 556-565	123
87	The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. **2017**, 31, 663-680	26
86	The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. **2017**, 98, 330-336	54
85	How I treat FLT3-mutated AML. **2017**, 129, 565-571	52
84	Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. **2017**, 10, 863-874	15

83	Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?. **2017**, 12, 413-447	18
82	Selecting initial treatment of acute myeloid leukaemia in older adults. **2017**, 31, 43-62	58
81	Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC. **2017**, 118, 1174-1181	4
80	High expression of FLT3 is a risk factor in leukemia. **2018**, 17, 2885-2892	21
79	Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. **2017**, 4, 48	23
78	FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. **2017** , 8, 10931-10944	22
77	The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis. **2017**, 18,	50
76	Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia. **2017**, 5, 248	16
75	Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. **2017**, 6,	28
74	Emerging therapies for acute myeloid leukemia: translating biology into the clinic. **2017**, 2,	21
73	Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment. **2017**, 18,	18
72	Analysis of the presence of FLT3 gene mutation and association with prognostic factors in adult and pediatric acute leukemia patients. **2017**, 53,	3
71	Mutation of the DNMT3A and IDH1/2 genes in Iranian acute myeloid leukemia patients with normal karyotype (CN-AML): association with other gene mutation and clinical and laboratory characteristics. **2018**, 11, 29-36	1
70	ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. **2018**, 14, 1995-2004	18
69	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. **2018**, 124, 306-314	17
68	The impact of FLT3 mutations on treatment response and survival in Chinese de□novo AML patients. **2018**, 23, 131-138	3
67	Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. **2018**, 109, 3981-3992	6
66	A comprehensive review of protein kinase inhibitors for cancer therapy. **2018**, 18, 1249-1270	87

65	Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. **2018**, 19,		30
64	FLT3 receptor/CD135 expression by flow cytometry in acute myeloid leukemia: Relation to FLT3 gene mutations and mRNA transcripts. **2018**, 19, 345-351		2
63	Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. **2018**, 191, 123-134		21
62	Targeting FLT3 Mutations in Acute Myeloid Leukemia. **2018**, 7,		24
61	Discovery of the selective and efficacious inhibitors of FLT3 mutations. **2018**, 155, 303-315		13
60	Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. **2019**, 110, 566-574		10
59	Conformational modifications induced by internal tandem duplications on the FLT3 kinase and juxtamembrane domains. **2019**, 21, 18467-18476		5
58	Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. **2019**, 62, 11135-11150		3
57	Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia. **2019**, 24, 651-660		5
56	inhibitor quizartinib (AC220). **2019**, 60, 1866-1876		9
55	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. **2019**, 10, 2040620719827310		63
54	Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. **2019**, 28, 337-349		9
53	Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. **2019**, 62, 875-892		14
52	Novel Approaches to Target Mutant FLT3 Leukaemia. *Cancers*, **2020**, 12,	6.6	2
51	Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress. **2020**, 20, 250		2
50	A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. **2020**, 193, 112232		5
49	Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy. **2020**, 10, 443		1
48	Emerging pharmacotherapies for elderly acute myeloid leukemia patients. **2020**, 13, 619-643		3

47	Gilteritinib: potent targeting of FLT3 mutations in AML. **2020**, 4, 1178-1191		35
46	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. *Cancers*, **2020**, 12,	6.6	2
45	Potential targeting of FLT3 acute myeloid leukemia. **2021**, 106, 671-681		11
44	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. **2021**, 35, 2517-2525		10
43	FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. **2021**, 64, 2878-2900		12
42	FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. *Blood Cancer Journal*, **2021**, 11, 104	7	14
41	CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells. **2021**, 125, 966-974		3
40	Importance of targeted therapies in acute myeloid leukemia. **2021**, 107-133		0
39	Poor Outcome of Pediatric Patients with Acute Myeloid Leukemia Harbour High FLT3/ITD Allelic Ratios.		
38	Receptor tyrosine kinase alterations in AML - biology and therapy. **2010**, 145, 85-108		9
37	Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. **2003**, 532, 121-40		24
36	New molecular therapy targets in acute myeloid leukemia. **2007**, 176, 243-62		6
35	Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. **2013**, 8, e66378		18
34	Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. **2019**, 10, 6111-6123		17
33	Bench to bedside targeting of FLT3 in acute leukemia. **2010**, 11, 781-9		31
32	Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia. **2019**, 20, 1749-1755		4
31	Recent advances and novel agents for FLT3 mutated acute myeloid leukemia. **2014**, 1, 7		7
30	Molecular involvement and prognostic importance of fms-like tyrosine kinase 3 in acute myeloid leukemia. **2012**, 13, 4215-20		3

29	Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia. **2015**, 16, 4869-72		6
28	FLT3: A Prototype Receptor Tyrosine Kinase Target in AML. **2007**, 247-261		
27	Acute Myeloid Leukemias with Normal Cytogenetics. **2010**, 449-462		
26	Molecularly Targeted Therapy for Infant ALL. **2010**, 31-58		
25	Protein Kinase Inhibitors in Drug Discovery. 1		
24	FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia. **2011**, 189-202		1
23	FLT3 in AML. **2015**, 215-231		
22	Outcome of Inversion 16 in TKD Positive and Negative Acute Myeloid Leukemia Patients. **2016**, 17, 2343-4		
21	FLT3 Inhibitors. **2017**, 167-179		
20	A review of FLT3 inhibitors in acute myeloid leukemia. **2021**, 52, 100905		3
19	Treatment of FLT3-ITD acute myeloid leukemia. **2011**, 1, 175-89		26
18	FLT3/ITD associated with an immature immunophenotype in PML-RAR□leukemia. *Hematology Reports*, **2012**, 4, e22	0.9	2
17	Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants. *Iranian Journal of Basic Medical Sciences*, **2014**, 17, 867-73	1.8	4
16	Screening of C-kit gene Mutation in Acute Myeloid Leukaemia in Northern India. *Iranian Journal of Cancer Prevention*, **2012**, 5, 27-32		1
15	FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. *Nagoya Journal of Medical Science*, **2015**, 77, 7-17	0.7	35
14	Lack of FLT3-TKD835 gene mutation in toxicity of sulfur mustard in Iranian veterans. *Iranian Journal of Basic Medical Sciences*, **2015**, 18, 862-6	1.8	2
13	Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy.. *Cancer Journal (Sudbury, Mass)*, **2022**, 28, 14-20	2.2	0
12	A novel approach for relapsed/refractory FLT3 acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.. *Molecular Cancer*, **2022**, 21, 66	42.1	0

11	Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies.		0
10	FLT3/ITD Associated with an Immature Immunophenotype in PML-RARLeukemia. *Hematology Reports*, **2012**, 4, e22	0.9	4
9	Target Therapy for Extramedullary Relapse of -ITD Acute Myeloid Leukemia: Emerging Data from the Field.. *Cancers*, **2022**, 14,	6.6	0
8	Resistance to targeted therapies: delving into FLT3 and IDH. *Blood Cancer Journal*, **2022**, 12,	7	1
7	Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios. *Nature Communications*, **2022**, 13,	17.4	0
6	Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. *Cancers*, **2022**, 14, 3456	6.6	3
5	Evolution of GravesDisease during Immune Reconstitution following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation in a Boy Carrying Germline SAMD9L and FLT3 Variants. **2022**, 23, 9494		0
4	Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challenges. **2022**,		0
3	Relation between FMS-like tyrosine kinase 3 factor and hematological parameter in acute lymphoblastic leukemia patients by flow cytometry. **2022**, 11, 175		0
2	Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. Volume 15, 1449-1478		0
1	Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies. **2023**, 16,		0